New structure allows leading Omega-3 oil company to have more strategic focus
LYSAKER, Norway (March 01, 2006) - EPAX AS, formerly a division of Pronova Biocare, announced today a recent de-merger from its previous parent company.
A producer of concentrated Omega-3 EPA/DHA oils in the business-to-business segment, EPAX AS will continue to produce its high quality, high purity oils under the EPAX brand name.
"We are excited about what our new structure means for our customers," said Bjorn Refsum, CEO, EPAX AS. "As our own company, we are able to solely focus on producing the highest quality Omega-3 oils and have full control over tailoring the services we offer to customers."
Refsum said despite the new structure, much has stayed the same. EPAX AS is still located in the same Lysaker location, its EPAX executive team is unchanged and the focus on high-quality Omega-3 oils for which EPAX is known is evident in the company's continued commitment to research and development. Customers can also count on EPAX¹s high level of customer service to remain the same.
The de-merger announcement comes at an ideal time for EPAX AS, as EPAX products just experienced a banner year with an astounding 25 percent growth in 2005, compared with the 2005 industry average of eight to 8.7 percent (Frost and Sullivan/Euromonitor).
"Our EPAX oils had a tremendous year," said Refsum. "The market is showing an increasing demand for Omega-3 oils that exceed the standards for purity in the industry. This is great news for consumers who are taking Omega-3 supplements."
About Epax AS: Headquartered in Lysaker, Norway, EPAX AS offers concentrated Omega-3 EPA/DHA oils in the business-to-business segment under the brand name EPAX. The oils are available in a wide range of top quality formulas with different EPA/DHA ratios focused on specific health conditions. EPAX is available in TG or EE versions.
At EPAX AS, each production run of Omega-3 carries full quality control documentation to ensure that the highest purity and quality standards are maintained. Analyses take place at every crucial stage and the most stringent, hygienic conditions are applied throughout Epax AS' operations.
EPAX products are produced in the cGMP certified state-of-the-art facilities to meet the highest quality standards possible. The products comply with the CRN voluntary monograph and all other known regulations. EPAX AS has gone beyond these standards and recently lowered the limits for all relevant organic pollutants and heavy metals in the product specification to reflect the company's commitment to purity.
In addition to its Lysaker headquarters, EPAX AS has a GMP approved production facility in Alesund, Norway, which is approved for API production by the Norwegian Medicines Agency. For further information on EPAX AS, its products or clinical studies visit www.epax.com or contact Gunilla Traberg at [email protected]
# # #
P.O. Box 420, N-1327
+ 47 22 53 4850